



PolyNovo Limited  
ABN 96 083 866 862  
2/320 Lorimer Street  
Port Melbourne  
VIC Australia 3207  
P +61 (0) 3 8681 4050  
F +61 (0) 3 8681 4099

10 January 2023

## ASX Announcement

### Presentation to J.P. Morgan Healthcare Conference

PolyNovo Limited (ASX: PNV, PolyNovo, the Company) today advises it is presenting at the 41<sup>st</sup> Annual J.P. Morgan Healthcare Conference (9-12 January) in San Francisco.

The presentation will take place on Wednesday 11 January 2023 at 7.30am PST (Thursday 12 January 2.30am AEDT). A live webcast and recording will be available at the following link:

[https://jpmorgan.metameetings.net/events/healthcare23/sessions/44365-polynovo/webcast?gpu\\_only=true&kiosk=true](https://jpmorgan.metameetings.net/events/healthcare23/sessions/44365-polynovo/webcast?gpu_only=true&kiosk=true)

The company is being represented by Chairman David Williams and CEO Swami Raote.

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

#### About PolyNovo®

PolyNovo is a disruptive medical device company, focused on Advanced Wound Care. PolyNovo is an Australian based medical device company that designs, develops, and manufactures dermal regeneration solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopedic applications. For further information and market presentations see [www.polynovo.com](http://www.polynovo.com)

#### About NovoSorb®

NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn. NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.